Alvimedica’s 2-mm Cre8 Evo DES Receives CE Mark Approval


February 4, 2019—Alvimedica announced European CE Mark approval of its 2-mm Cre8 EVO drug-eluting stent, further enlarging the company's polymer-free, amphilimus-eluting stent portfolio and offering physicians more extensive treatment coverage for patients with complex coronary artery disease.

According to the company, the device’s ultra-thin 70 µm total stent strut minimizes metal volume in small coronaries, and its design meets the specific device deliverability, conformability to the vessel, and mechanical performance required for 2-mm vessels. Because of its unique cell geometry, the device can be implanted in challenging tapered and tortuous vessels and side branches.

Leyla Alaton, President and CEO of Alvimedica, commented, “We are taking the challenge to develop devices that answer the real, everyday clinical unmet needs in a global scenario. The patient population suffering from coronary disease increases every year, [and] its clinical need may be different according to the clinical conditions, disease location, and geographical area.”


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.